Cagrilintide is an amylin analog currently under development, intended to be used in combination with the GLP-1 agonist semaglutide to achieve sustained weight loss in individuals with overweight and obesity. In clinical trials, cagrilintide has shown significant weight loss effects when used alone or in combination with semaglutide. This combination medication, known as CagriSema, is a recombinant and synthetic peptide commercialized by Novo Nordisk, with a leading Phase III program targeting Type 2 Diabetes.
Cagrilintide mimics the action of amylin, a hormone produced by the pancreas that promotes feelings of satiety or fullness after eating. It is a non-selective agonist formulated at low pH for subcutaneous injection once a w...
